



# Stimunity Received a Non-Dilutive Financing from Scientipôle Initiative

Paris, June 24, 2016 -- Stimunity is pleased to announce that the company has received a non-dilutive financing of 60k€ from Scientipôle Initiative to complete the proof-of-concept package.

It is unusual that Scientipôle Initiative finances projects in the biotech sector, due to the high quantity of capital required in this industry. However, in the case of Stimunity, the jury was convinced that this initial financing will move the project to the next milestone, and will strongly reinforce the position of the cofounders before a first investment. Sylvain Carlioz, CEO, explains, "This money will contribute to finance a series of experiments that will complete the proof-of-concept package of our approach *in vivo*, which is key to convince private investors to take the risk of financing the next preclinical milestone".

This non-dilutive financing is very welcome as it also reinforces the equity position of the co-founders in the company and will help to leverage this financing with public money. "The difficulty in France is to find the 1<sup>st</sup> euro as public money for good projects is only available if the company has significant capital, which is of course very difficult to have as a startup" says Sylvain.

## About Scientipôle



Scientipôle, helping Paris Region-based innovative startups get to their first million in sales in 3 years.

Supported by the Paris Region Council, Scientipôle provides early stage startups with non-dilutive funding and business development services to help them differentiate and succeed. The accelerator grants zero rate loans and brings together a close-knit community of corporate & public partners and successful entrepreneurs to help them get to their first million in annual sales in less than 3 years. Over the past 5 years, Scientipôle has supported 600+ startups with a total of € 30 million in loans, helping them create over 5,000 jobs. Scientipôle's Portfolio includes successful startups such as BlablaCar, Rue89,



Run My Process, Alkemics, Ynsect, Naskeo, Novapost, Dataïku, Airinov, Deliver.ee, Damae Medical, Softcorner, Prestodiag, and many more.

More information: [www.scientipole-initiative.org](http://www.scientipole-initiative.org) - [www.scientipole-croissance.org](http://www.scientipole-croissance.org).  
Contact: [clara.missoffe@scientipole-croissance.org](mailto:clara.missoffe@scientipole-croissance.org).

## About Stimunity



Stimunity is a startup company from Institut Curie which develops biopharmaceuticals to treat patients that still do not respond to conventional immunotherapy in infectious disease and cancer. Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique biologic approach which combines the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunity's drugs are best-in-class.

More information at <http://stimunity.com> or [sylvain.carlioz@stimunity.com](mailto:sylvain.carlioz@stimunity.com).

-----